Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or tips

Digestive Diseases and Sciences

Volumn 56, Issue 4, 2011, Pages 977-987

  Al Sibae, Mohamad R ^a   Cappell, Mitchell S ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Alcoholic hepatitis; Cirrhosis; Hepatorenal syndrome; Liver failure; Liver transplantation; MELD score; Non liver transplant surgery; TIPS; Variceal bleeding

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE; SODIUM;

ACUTE LIVER FAILURE; ALBUMIN BLOOD LEVEL; ALCOHOL LIVER DISEASE; APACHE; BILIRUBIN BLOOD LEVEL; CLINICAL DECISION MAKING; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; ESOPHAGUS VARICES; GASTROESOPHAGEAL VARICEAL HEMORRHAGE; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; ORGAN DONOR; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SODIUM BLOOD LEVEL; SYSTEMATIC REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

BILIRUBIN; CREATININE; END STAGE LIVER DISEASE; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HEPATITIS, ALCOHOLIC; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE, ACUTE; MALE; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; PROTHROMBIN TIME; SEVERITY OF ILLNESS INDEX;

EID: 79955596949     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-010-1390-3     Document Type: Review

References (88)

1. Londono MC, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006;130(4):1135-1143.
2. www.unos.org. Accessed July 5, 2010.
3. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864-871.
4. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-470. (Pubitemid 32119037)
5. Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8(9):851-858.
6. Trotter JF, Brimhall F, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for end-stage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl. 2004;10(8):995-1000. (Pubitemid 39232753)
7. Cholongitas E, Marelli L, Kerry A, et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl. 2007;13(4):523-529. (Pubitemid 46605854)
8. Goulding C, Cholongitas E, Nair D, et al. Assessment of reproducibility of creatinine measurement and MELD scoring in four liver transplant units in the UK. Nephrol Dial Transpl. 2010;25(3):960-968.
9. www.unos.org/resources/MeldPeldcalculator.asp?index=98.
10. Freeman RB Jr, Gish RG, Harper A, et al. Model for end-stage liver disease (MELD) exception guidelines: results, recommendations from the MELD exception study group, conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl. 2006;12:S128.
11. Volk ML, Lok AS, Pelletier SJ, et al. Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology. 2008;135(5):1568-1574.
12. Shakil AO, Kramer D, Mazariegos JV, Fung J, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000;6:163-169. (Pubitemid 30173994)
13. Bernal W, Wendon J. Liver transplantation in adults with acute liver failure. Hepatology. 2004;40:192-197. (Pubitemid 38115821)
14. Riorden S, Williams R. Mechanism of hepatocyte injury, multi-organ failure, and prognostic criteria in acute liver failure. Semin Liver Dis. 2003;23:203-216.
15. Dhiman R, Seth A, Jain S, Chawla YK, Dilawari JB. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig Dis Sci. 1998;43:1311-1316. (Pubitemid 28272568)
16. Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver failure. Hepatology. 2005;41:26-31. (Pubitemid 40066379)
17. Neuberger J. Prediction of survival for patients with fulminant hepatic failure. Hepatology. 2005;41:19-22. (Pubitemid 40066377)
18. Kremers WK, van Liperen M, Kim WR, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology. 2004;39(3):764-769. (Pubitemid 38337656)
19. Yantorno SET, Trentadue JJ, Ruf AE, et al. The model for end stage liver disease (MELD): a useful tool to assess prognosis in fulminant hepatic failure. Liver Transpl. 2004;10:C36.
20. Schmidt LE, Larsen FS. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology. 2007;45(3):789-796. (Pubitemid 46450630)
21. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-782. (Pubitemid 30118650)
22. Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007;65:S57-S63.
23. Garrison RN, Cryer HM, Howard DA, Polk HC Jr. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg. 1984;199(6):648-655. (Pubitemid 14112385)
24. Ziser A, Plevak DJ, Wiesner RH, et al. Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology. 1999;90:42-53.
25. Durand F. Risk scores in cirrhotic patients: from non-transplant surgery to transplantation and back. J Hepatol. 2006;44:620-621. (Pubitemid 43227890)
26. Friedman LS, Maddrey WC. Surgery in the patient with liver disease. Med Clin North Am. 1987;71:453-476. (Pubitemid 17106741)
27. Patel T. Surgery in the patient with liver disease. Mayo Clin Proc. 1999;74:593-599.
28. Teh SH, Nagorney DM, Stevens SR, et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology. 2007;132(4):1261-1269. (Pubitemid 46627576)
29. Northup PG, Wanamaker RC, Lee VD, et al. Model for end-stage liver disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg. 2005;242:244-251. (Pubitemid 41033441)
30. Farnsworth N, Fagan SP, Berger DH, Awad SS. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg. 2004;188(5):580-583. (Pubitemid 39491109)
31. Dells S, Bakoylannis A, Madariaga J, Bramis J, Tassopoulos N, Dervenis C. Laparoscopic cholecystectomy in cirrhotic patients: the value of MELD score and Child-Pugh classification in predicting outcome. Surg Endosc. 2010;24(2):407-412.
32. Perkins L, Jeffries M, Patel T. Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis. Clin Gastroenterol Hepatol. 2004;2(12):1123-1128. (Pubitemid 40037644)
33. Befeler AS, Palmer DE, Hoffman M, Longo W, Solomon H, Di Bisceglie AM. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. Arch Surg. 2005;140(7):650-654. discussion 655.
34. Cucchetti A, Ercolani G, Vivarelli M, et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl. 2006;12(6):966-971. (Pubitemid 43960373)
35. Hanje AJ, Patel T. Preoperative evaluation of patients with liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;4(5):266-276. (Pubitemid 46711464)
36. Rösch J, Keller FS. Transjugular intrahepatic portosystemic shunt: present status, comparison with endoscopic therapy and shunt surgery, and future prospectives. World J Surg. 2001;25(3):337-346.
37. Shiffman ML, Jeffers L, Hoofnagle JH, Tralka TS. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: conference sponsored by the National Digestive Diseases Advisory Board. Hepatology. 1995;22:1591-1597.
38. Rösch J. The creation of TIPS: a brief history. In: Conn HO, Palmaz JC, Rosch J, Rossle M, eds. TIPS transjugular intrahepatic portosystemic shunts. New York: Igaku-Shoin; 1996:55-64.
39. Salerno F, Merli M, Cazzaniga M, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol. 2002;36:494-500. (Pubitemid 34407337)
40. Alessandria C, Gaia S, Marzano A, Venon WD, Fadda M, Rizzetto M. Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. Eur J Gastroenterol Hepatol. 2004;16:607-612. (Pubitemid 38703870)
41. Angermayr B, Cejna M, Karnel F, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003;52:879-885. (Pubitemid 36613497)
42. Montgomery A, Ferral H, Vasan R, Postoak DW. MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures. Cardiovasc Intervent Radiol. 2005;28(3):307-312. (Pubitemid 40880749)
43. Ferral H, Gamboa P, Postoak DW, et al. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology. 2004;231(1):231-236. (Pubitemid 38375433)
44. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-699. (Pubitemid 26079803)
45. Cheng SJ, Pratt DJ, Freeman RB Jr, Kaplan MM, Wong JB. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation. 2001;72(5):861-868.
46. Christensen E. Prognostic models in chronic liver disease: validity, usefulness and future role. J Hepatol. 1997;26:1414-1424. (Pubitemid 27346659)
47. Sanyal AJ, Genning C, Reddy KR, et al. The North American Study for the treatment of refractory ascites. Gastroenterology. 2003;124:634-641. (Pubitemid 36268482)
48. Albillos A, Colombato LA, Groszmann RJ. Vasodilation and sodium retention in prehepatic portal hypertension. Gastroenterology. 1992;102:931-935.
49. Londono MC, Cardenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56:1283-1290. (Pubitemid 47300431)
50. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41:32-39. (Pubitemid 40066380)
51. Gunsar F, Raimondo ML, Jones S, et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther. 2006;24:563-572. (Pubitemid 44127837)
52. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;42(suppl):S100-S107. (Pubitemid 40364609)
53. Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology. 1994;20:119-125. (Pubitemid 24196500)
54. Holstein A, Hinze S, Thiessen E, et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol. 2002;17:677-681. (Pubitemid 34748159)
55. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systemic review of 118 studies. J Hepatol. 2006;44:217-231. (Pubitemid 41772537)
56. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481-488. (Pubitemid 47187350)
57. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40(4):802-810. (Pubitemid 39288112)
58. Hsu CY, Lin HC, Huang YH, et al. Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Dig Liver Dis. 2010;42(2):137-142.
59. Merli M, Riggio O, Dally L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi). Hepatology. 1996;23:1041-1046.
60. Samuelson AL, Lee M, Kamal A, Keeffe EB, Ahmed A. Diabetes mellitus increases the risk of mortality following liver transplantation independent of MELD score. Dig Dis Sci. 2010;55(7):2089-2094.
61. Jiang M, Liu F, Xiong WJ, et al. Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis. World J Gastroenterol. 2010;16(11):1397-1401.
62. Zipprich A, Kuss O, Rogowski S, et al. Incorporating indocyanine green clearance into the model for end stage liver disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis. Gut. 2010;59(7):963-968.
63. Munoz SJ, Stravitz RT, Gabriel DA. Coagulopathy of acute liver failure. Clin Liver Dis. 2009;13(1):95-107.
64. Porte RJ, Lisman T, Tripodi A, Caldwell SH, Trotter JF. and the Coagulation in Liver Disease Study Group. The international normalized ratio (INR) in the MELD score: problems and solutions. Am J Transpl. 2010;10:1349-1353.
65. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229-236. (Pubitemid 23234041)
66. Badalamenti S, Graziani G, Salerno F, Ponticelli C. Hepatorenal syndrome: new perspectives in pathogenesis and treatment. Arch Intern Med. 1993;153(17):1957-1967. (Pubitemid 23263557)
67. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation. 1991;51(2):428-430.
68. Kalambokis G, Economou M, Fotopoulos A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005;100(4):879-885.
69. Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int. 2005;68(1):362-370. (Pubitemid 43181396)
70. Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-1318. (Pubitemid 47300435)
71. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23(1):164-176.
72. Arroyo V, Guevara M, Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology. 2002;122(6):1658-1676.
73. Ginés P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology. 1987;93(2):234-241. (Pubitemid 17097585)
74. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005;41(6):1282-1289. (Pubitemid 40770280)
75. Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol. 2009;15(28):3462-3471.
76. Carithers RJ Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med. 1989;110:685-690. (Pubitemid 19121221)
77. Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology. 1993;17:564-576. (Pubitemid 23115499)
78. Hislop WS, Bouchier IA, Allan JG, et al. Alcoholic liver disease in Scotland and northeastern England: presenting features in 510 patients. Q J Med. 1983;52(206):232-243. (Pubitemid 14248297)
79. Stewart S, Prince M, Bassendine M, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol. 2007;47:277-283. (Pubitemid 47021256)
80. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193-199. (Pubitemid 8372264)
81. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41(2):353-358. (Pubitemid 40165379)
82. Sheth M, Riggs M, Patel T. Utility of the Mayo end-stage liver disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol. 2002;2(1):2.
83. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol. 2005;42(5):700-706.
84. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med. 1988;319:983-989.
85. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990;99:1401-1407. (Pubitemid 20381877)
86. Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology. 1989;96:1552-1559. (Pubitemid 19138700)
87. Amitrano L, Guardascione MA, Bennato R, Manguso F, Balzano A. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. J Hepatol. 2005;42(6):820-825. (Pubitemid 40693198)
88. Bambha K, Kim WR, Pedersen R, Bida JP, Kremers WK, Kamath PS. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut. 2008;57(6):814-820. (Pubitemid 351716977)